Drug
Alirocumab Praluent
Alirocumab Praluent: highest development phase Phase 3, developed by United Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Alirocumab 150 MG/ML [Praluent] NCT03480568 | Phase 3 | Hemodialysis |
Latest
No recent events.
Follow Alirocumab Praluent on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.